Subtype
Primary Central Nervous System Neoplasm
CI-CAN-00001432Explore in graph →
Non-malignant957 active trials5 approved drugs175 evidence items
- NCIt
- C102871
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001432Explore in graph →
Clinical trials
3,294 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03255018 | Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 28, 2023 | clinicaltrials |
| NCT03458312 | Nurse-led Family and Network Consultations(CARES) | completed | N/A | 114 | Rigshospitalet, DenmarkOTHER | 1 | Nov 28, 2023 |
| clinicaltrials |
| NCT01502280 | Fluorescence-guided Surgery for Low- and High-grade Gliomas(BALANCE) | completed | Phase 3 | 127 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03027388 | Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma | completed | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03706625 | Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment(IDeATIon) | completed | — | 201 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT01957956 | Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | completed | Early Phase 1 | 21 | Mayo ClinicOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02315534 | A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma | completed | Phase 1 / Phase 2 | 34 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Nov 15, 2023 | clinicaltrials |
| NCT03149003 | A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy | completed | Phase 3 | 221 | Sumitomo Pharma America, Inc.INDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT02498665 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | completed | Phase 1 | 24 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT03425292 | A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer | completed | Phase 1 | 49 | Saint John's Cancer InstituteOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT00019578 | Stereotactic Radiosurgery in Treating Patients With Brain Tumors | completed | Phase 1 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02644460 | Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors(AflacST1501) | completed | Phase 1 | 53 | Emory UniversityOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT03557372 | Mathematical Model-Adapted Radiation In Glioblastoma | completed | N/A | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT02313272 | Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas | completed | Phase 1 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT02780804 | Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT02575794 | Terameprocol in Treating Patients With Recurrent High Grade Glioma | completed | Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT02658981 | Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) | completed | Phase 1 | 63 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT01491893 | PVSRIPO for Recurrent Glioblastoma (GBM)(PVSRIPO) | completed | Phase 1 | 61 | Istari Oncology, Inc.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03158389 | NCT Neuro Master Match - N²M² (NOA-20)(N²M²) | completed | Phase 1 / Phase 2 | 228 | University Hospital HeidelbergOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 2 | Sep 26, 2023 | clinicaltrials |
| NCT05873946 | Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery(2D-ioUS-Glio) | completed | — | 99 | Hospital del Rio HortegaOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT04119674 | Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 33 | Zhejiang Cancer HospitalOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02386826 | INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme | completed | Phase 1 | 65 | SCRI Development Innovations, LLCOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01493219 | Biomarkers for Prognosis of Glioblastoma (GBM) | completed | — | 19 | University of NebraskaOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT03841435 | Hypofractionated Radiotherapy for Recurrent DIPG | completed | N/A | 5 | University of CincinnatiOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT04478877 | Establishment and Characterization of Meningioma Patient-derived Organoids | completed | — | 20 | Chinese University of Hong KongOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT03953131 | Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas | completed | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT00634231 | A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors | completed | Phase 1 | 8 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT00751270 | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas(BrTK01) | completed | Phase 1 | 15 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT01259869 | A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression | completed | Phase 2 | 34 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 22, 2023 | clinicaltrials |
| NCT05039346 | Quality of Life and Patient Needs in Advanced High Grade Gliomas | completed | — | 55 | Henry Ford Health SystemOTHER | 0 | Aug 14, 2023 | clinicaltrials |
| NCT02619864 | mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme | completed | Phase 1 | 15 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03538587 | Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers | completed | N/A | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02330991 | A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse | completed | Phase 2 | 204 | Beijing Sanbo Brain HospitalOTHER | 0 | Jul 24, 2023 | clinicaltrials |
| NCT04659421 | Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas | completed | Phase 2 | 60 | Beijing Sanbo Brain HospitalOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT04814329 | Glioblastoma Response Prediction to Apatinib | completed | — | 18 | Beijing Sanbo Brain HospitalOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05718466 | Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy | completed | Phase 3 | 35 | Henry Ford Health SystemOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT01290692 | Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma | completed | Phase 2 | 14 | TVAX BiomedicalINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT01466686 | Low Dose Radiation Therapy for Glioblastoma Multiforme | completed | Phase 2 | 31 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT02022644 | Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma | completed | Phase 1 | 18 | University of California, San FranciscoOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT03360708 | Vaccine Therapy in Treating Patients With Recurrent Glioblastoma | completed | Early Phase 1 | 20 | Mayo ClinicOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT03726515 | CART-EGFRvIII + Pembrolizumab in GBM | completed | Phase 1 | 7 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02661282 | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | completed | Phase 1 / Phase 2 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03032484 | TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma | completed | Phase 2 | 25 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT04757662 | Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma | completed | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT05896449 | Predictive Values of Preoperative [68Ga]Ga-PSMA-11 PET/CT in Patients With Suspected Brain Tumours of Glial Origin | completed | N/A | 49 | Medical University of WarsawOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT02366728 | DC Migration Study for Newly-Diagnosed GBM(ELEVATE) | completed | Phase 2 | 64 | Mustafa Khasraw, MBChB, MD, FRCP, FRACPOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT03915912 | Mindfulness Meditation in Glioma Patients | completed | N/A | 17 | Duke UniversityOTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT00662506 | Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2023 | clinicaltrials |
| NCT01081223 | Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma | completed | Phase 1 / Phase 2 | 12 | TVAX BiomedicalINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 28, 2023source: clinicaltrials